ADC Enters the 2.0 Era: From Enhertu to Multi-Payload Platform Competition

By:DengYue International Business Division

As global drug innovation moves into a deeper, more competitive phase, antibody-drug conjugates (ADCs) have evolved from isolated breakthroughs into a full-scale technology platform race. Over the past decade, ADCs have transitioned from “proof of concept” to “how to optimize at scale.” Today, competition around antibody drug conjugates 2026, ADC pipeline global, and HER2 ADC drugs is no longer about a single product—but about the combined strength of platform capability, clinical strategy, and commercialization efficiency.

As a key bridge connecting Chinese innovation with global clinical demand, DengYueMed continues to track ADC advancements and improve cross-border accessibility, helping cutting-edge therapies reach real-world patients faster—while also supporting the global visibility of innovative drugs emerging from China.

1. From ADC 1.0 to 2.0: No Longer a Drug, but an Engineered System

The three core components of ADCs—antibody + linker + payload—were once treated as modular parts. In the 2.0 era, they are engineered as an integrated system.

Key limitations in the 1.0 era:

● Antibody selection lacked precise patient stratification

● Linker instability led to off-target toxicity

● Payloads were highly potent but had narrow therapeutic windows (e.g., MMAE, DM1)

● Drug-to-antibody ratio (DAR) was poorly controlled

A representative example is Kadcyla, which achieved commercial success but faced limitations in efficacy expansion.

Core breakthroughs in the 2.0 era:

Led by Enhertu, ADC design now reflects system-level optimization:

● High DAR (~8) with maintained stability

● Tumor-selective payload release mechanisms

● Membrane-permeable payloads enabling strong bystander effect

● Clinical strategy moving earlier in treatment lines

ADCs have evolved from “targeted cytotoxics” into precision delivery systems, with increasing platform scalability across indications.

2. The Core of Innovation: Nonlinear Integration of the Three Components

The defining feature of ADC 2.0 is not incremental improvement—but co-optimization.

2.1 Payload: From Maximum Toxicity to Tunable Cytotoxicity

The focus has shifted from “most potent” to “most controllable”:

● Topoisomerase I inhibitors (e.g., deruxtecan)

● RNA polymerase inhibitors

● Novel DNA-damage mechanisms

Key trends:

● Matching toxicity with pharmacokinetics

● Engineering membrane permeability → controls bystander effect

● Emergence of dual-payload ADCs

Dual payload strategies enable:

● Coverage of multiple cell-cycle phases

● Better handling of tumor heterogeneity

● Delayed resistance development

2.2 Linker: From Connector to Core Control Mechanism

In ADC 2.0, the linker is often the true differentiator:

● Enzyme-cleavable linkers

● pH-sensitive systems

● Self-immolative designs

Critical parameters:

● Stability in circulation

● Efficient release in tumor microenvironment

● Preservation of payload activity

Enhertu’s success is, in large part, a triumph of linker engineering.

2.3 Antibody: From Targeting Tool to Stratification Engine

Antibodies now play a broader role:

● Define patient eligibility (HER2-high → HER2-low)

● Influence internalization efficiency

● Enable immune modulation via Fc function

A major shift:Lower expression thresholds are now viable targets

This is why HER2 ADC drugs are expanding beyond breast cancer into:

● Gastric cancer

● Non-small cell lung cancer

● Colorectal cancer (under exploration)

3. Clinical Strategy Redefined: From Add-On to Core Treatment Axis

3.1 Earlier Line Usage

● Moving from third-line to first-line

● Entering neoadjuvant and adjuvant settings

3.2 Combination Therapy as Standard

● ADC + PD-1/PD-L1

● ADC + low-dose chemotherapy

● ADC + targeted therapy

Mechanism:

● Induction of immunogenic cell death (ICD)

● Dual effect: antigen release + immune activation

3.3 Indication Expansion Logic Shift

Old model:

High expression target → specific cancer

New model:

Efficient delivery platform → multiple cancers

This paradigm shift is central to the expansion of the ADC pipeline global.

4. Global Competition: The Rise of Platform Wars

ADC competition has moved from products to platforms.

Global leaders:

● Daiichi Sankyo / AstraZeneca (Enhertu ecosystem)

● Seagen (acquired by Pfizer)

● Roche

Strengths:

● Deep technology stacks

● Strong clinical infrastructure

● Mature global commercialization

China’s Rise: From Fast-Follow to Innovation Leader

Chinese companies are rapidly gaining ground:

● RemeGen

○ RC48 validated in global markets

● Sichuan Baili Tianheng

○ Focus on platform-based and multi-payload ADCs

Key advantages:

● Faster clinical execution

● Strong CMC (manufacturing) optimization

● Active global licensing deals

China’s contribution to the ADC pipeline global continues to expand, with several candidates already appearing in the list of approved drugs in China or nearing approval.

Notably, many of these companies are also emerging among the top rare disease companies, as ADC platforms expand into niche and high-unmet-need indications.

5. Commercialization & Access: The “Last Mile” Challenge

Despite clinical success, ADCs face a major barrier: Cost and accessibility

Drugs like Enhertu remain expensive, limiting patient access worldwide.

In this context:

● Chinese ADCs offer cost-effective alternatives

● Cross-border pharmaceutical logistics becomes critical

● Cold-chain and regulatory compliance are essential

As a trusted platform operating within the global chinese online pharmacy ecosystem, DengYueMed supports:

● Global sourcing of innovative oncology drugs

● End-to-end cold-chain logistics

● Regulatory-compliant international distribution

This ensures that innovative drugs are not only developed—but actually reach patients in need.

6. Conclusion: Who Will Define ADC 3.0?

ADC 2.0 is about engineering and platforms. The next phase may include:

● Precisely controlled multi-payload systems

● Programmable linker technologies

● Integration with cell therapies

● AI-driven molecular design

Ultimately, the future of ADCs will not be defined by toxicity—but by:

The ability to build scalable, programmable, and globally deployable delivery platforms

In this transformation, DengYue will continue to connect global demand with Chinese innovation—tracking antibody drug conjugates 2026, integrating leading HER2 ADC drugs, and accelerating the journey from breakthrough science to real-world accessibility.